

The effect of nitrate supplementation on sarcoplasmic reticulum Ca²⁺ handling in dystrophic skeletal muscle fibres

R. Blazev,^{1,3} C.A. Timpani,¹ G.K. McConell,² A. Hayes^{1,2,3} and E. Rybalka,^{1,2,3} ¹Centre for Chronic Disease, College of Health & Biomedicine, Victoria University, VIC 8001, Australia, ²Institute of Sport, Exercise & Active Living (ISEAL), Victoria University, VIC 8001, Australia and ³Australian Institute of Musculoskeletal Sciences (AIMSS), Western Health, Sunshine, VIC 3020, Australia.

There is emerging evidence to suggest that dietary nitrate supplementation enhances skeletal muscle contractile performance and that nitrate may therefore have a potential therapeutic role in improving contractile function in diseased states (Hernandez *et al.*, 2012). In the present study, we used a mechanically skinned muscle fibre preparation to investigate whether nitrate supplementation affects sarcoplasmic reticulum (SR) function in *tibialis anterior* (TA) muscle of the *mdx* mouse; a commonly used animal model of Duchenne Muscular Dystrophy.

All experiments were approved by the Victoria University Animal Ethics Experimentation Committee. Four week old male wild-type (WT) C57BL/10 and dystrophic (*mdx*) C57BL/10*mdx* mice were given 1 mM NaNO₃ in drinking water for eight weeks (NITR), while non-supplemented mice were given drinking water without NaNO₃. At twelve weeks of age, mice were anaesthetized *via* intraperitoneal injection of sodium pentobarbitone (60 mg/Kg) and the TA muscle dissected. Skinned fibre solutions and experimental protocols were similar to that described by Trinh and Lamb (2006). Because single fibres were mechanically skinned under paraffin oil they retained their endogenous SR Ca²⁺ content, which was estimated from the time-integral (area) of the force response to 30 mM caffeine (with 0.05 mM free Mg²⁺ and 0.5 mM EGTA). The SR of skinned fibre segments could then be subjected to repeated cycles in which it was loaded with Ca²⁺ at pCa (= -log₁₀[Ca²⁺]) 6.7 (1 mM EGTA) for various times (10 – 120 s) and depleted with 30 mM caffeine, with the area of the ensuing force response indicative of the amount of Ca²⁺ sequestered by the SR. This area was normalized to the maximum Ca²⁺-activated force (F_{max}) to allow comparisons between fibres. Passive Ca²⁺ leak out of the SR was assessed from the time-integral of the 30 mM caffeine response obtained after the SR had been loaded with Ca²⁺ for a set time and then exposed to a leak solution (0.5 mM EGTA) to prevent SR Ca²⁺ uptake. Results are reported as mean ± SEM.

There was no effect of NITR on specific force (kN/m²) in either *mdx* (215.0 ± 17.9, *n* = 13 vs. NITR 237.9 ± 21.8, *n* = 12) or WT (284.5 ± 18.0, *n* = 10 vs. NITR 298.3 ± 17.9, *n* = 10) TA skinned muscle fibres. Nitrate supplementation did not alter the endogenous SR Ca²⁺ content of *mdx* skinned fibres (%F_{max}.s: 120.7 ± 28.2, *n* = 13 vs. 100.1 ± 30.2, *n* = 10), but did significantly increase the endogenous SR Ca²⁺ content of WT fibres (%F_{max}.s: 37.9 ± 12.9, *n* = 10 vs. NITR 253.3 ± 61.8, *n* = 10; *P*<0.05). In *mdx* fibres the ability of the SR to sequester Ca²⁺ after maximal loading at pCa 6.7 was significantly lower (*P*<0.05) following nitrate supplementation (%F_{max}.s: 871 ± 66.5, *n* = 13 vs. NITR 627.2 ± 40.9, *n* = 11), while no differences were observed in WT fibres (%F_{max}.s: 629.1 ± 112.1, *n* = 10 vs. NITR 637.6 ± 74, *n* = 10). The reduced maximum SR Ca²⁺ loading capacity observed in *mdx* fibres was not due to differences in passive Ca²⁺ leak from the SR (% leak: 29.9 ± 4.8, *n* = 13 vs. NITR 36.1 ± 6.1, *n* = 11), and there were no differences in leak observed in WT fibres with NITR (% leak: 24.2 ± 2.1, *n* = 10 vs. NITR 29.3 ± 5.7, *n* = 8).

Thus, nitrate supplementation in *mdx* mice appears to decrease the capacity of the SR to maximally sequester Ca²⁺ with no effect on specific force, endogenous SR Ca²⁺ content, or SR Ca²⁺ leak.

Hernández A, Schiffer TA, Ivarsson N, Cheng AJ, Bruton JD, Lundberg JO, Weitzberg E & Westerblad, H. (2012). *J Physiol* **590**, 3575-3583.

Trinh HH & Lamb GD. (2006). *Clin Exp Pharmacol Physiol* **33**,591-600.